Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing

List of Tables

The Asia Pacific biologics market was valued at US$ 1,01,590.5 million in 2023 and is expected to reach US$ 4,17,082.9 million by 2031; it is estimated to register a CAGR of 19.3% from 2023 to 2031.

Evolution of Biotechnology in Developing Regions Fuels Asia Pacific Biologics Market

Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.

Asia Pacific Biologics Market Overview

The biologics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in the region is driven by a large pool of patients living with genetic conditions and increasing investments in healthcare R&D by governments of respective countries. Over the past few years, there has been a significant rise in awareness about the benefits of biologics in China. Moreover, there was a rise in local access to a broad range of testing services for cell line characterization and many release from preclinical development to commercialization, creating a positive impact on the growth of the market. In recent years, scientists and health authorities have made efforts to highlight how biologics could be effectively utilized to study and treat diseases and develop pharmaceuticals and medical devices. They are also striving to strengthen their knowledge based on the mechanism of development of congenital disabilities. Samsung Biologics has signed a partnership agreement with China Biotech GeneQuantum Healthcare for the development of antibody-drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors.

Asia Pacific Biologics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Biologics Market Segmentation

The Asia Pacific biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Asia Pacific biologics market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Asia Pacific biologics market.

Product Code: BMIRE00031590

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Asia Pacific Biologics Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Preference for Outsourcing Manufacturing Operations
4.2 Market Restraints
- 4.2.1 High Cost of Biologics
4.3 Market Opportunities
- 4.3.1 Evolution of Biotechnology in Developing Regions
- 4.3.2 Gene and Cell Therapy Advancements in Biologics
4.4 Future Trends
- 4.4.1 Strategic Initiatives by Companies
4.5 Impact of Drivers and Restraints:

5. Biologics Market - Asia Pacific Analysis

5.1 Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
5.2 Asia Pacific Biologics Market Forecast Analysis

6. Asia Pacific Biologics Market Analysis - by Product

6.1 Monoclonal Antibodies
- 6.1.1 Overview
- 6.1.2 Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Vaccine
- 6.2.1 Overview
- 6.2.2 Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Recombinant Hormones/Proteins
- 6.3.1 Overview
- 6.3.2 Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Cell and Gene Therapy
- 6.4.1 Overview
- 6.4.2 Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Biologics Market Analysis - by Application

7.1 Cancer
- 7.1.1 Overview
- 7.1.2 Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Infectious Diseases
- 7.2.1 Overview
- 7.2.2 Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Autoimmune Diseases
- 7.3.1 Overview
- 7.3.2 Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Biologics Market Analysis - by Source

8.1 Mammalian
- 8.1.1 Overview
- 8.1.2 Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Microbial
- 8.2.1 Overview
- 8.2.2 Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Biologics Market Analysis - by Manufacturing

9.1 Outsourced
- 9.1.1 Overview
- 9.1.2 Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 In-house
- 9.2.1 Overview
- 9.2.2 In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Biologics Market - Country Analysis

10.1 Asia Pacific
- 10.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 China: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.2.1 China: Asia Pacific Biologics Market Share - by Product
    - 10.1.1.2.2 China: Asia Pacific Biologics Market Share - by Application
    - 10.1.1.2.3 China: Asia Pacific Biologics Market Share - by Source
    - 10.1.1.2.4 China: Asia Pacific Biologics Market Share - by Manufacturing
  - 10.1.1.3 India: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.3.1 India: Asia Pacific Biologics Market Share - by Product
    - 10.1.1.3.2 India: Asia Pacific Biologics Market Share - by Application
    - 10.1.1.3.3 India: Asia Pacific Biologics Market Share - by Source
    - 10.1.1.3.4 India: Asia Pacific Biologics Market Share - by Manufacturing
  - 10.1.1.4 Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.4.1 Japan: Asia Pacific Biologics Market Share - by Product
    - 10.1.1.4.2 Japan: Asia Pacific Biologics Market Share - by Application
    - 10.1.1.4.3 Japan: Asia Pacific Biologics Market Share - by Source
    - 10.1.1.4.4 Japan: Asia Pacific Biologics Market Share - by Manufacturing
  - 10.1.1.5 South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.5.1 South Korea: Asia Pacific Biologics Market Share - by Product
    - 10.1.1.5.2 South Korea: Asia Pacific Biologics Market Share - by Application
    - 10.1.1.5.3 South Korea: Asia Pacific Biologics Market Share - by Source
    - 10.1.1.5.4 South Korea: Asia Pacific Biologics Market Share - by Manufacturing
  - 10.1.1.6 Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.6.1 Australia: Asia Pacific Biologics Market Share - by Product
    - 10.1.1.6.2 Australia: Asia Pacific Biologics Market Share - by Application
    - 10.1.1.6.3 Australia: Asia Pacific Biologics Market Share - by Source
    - 10.1.1.6.4 Australia: Asia Pacific Biologics Market Share - by Manufacturing
  - 10.1.1.7 Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Product
    - 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Application
    - 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Source
    - 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Manufacturing

11. Industry Landscape

11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments

12. Company Profiles

12.1 AbbVie Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Pfizer Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Samsung Biologics Co Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 ADMA Biologics, Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 WuXi Biologics Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 AGC Biologics AS
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 AstraZeneca Plc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Amgen Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Nitto Avecia
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Quality Assistance s.a.
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

13. Appendix

13.1 About Us